Notice of Annual General Meeting of Shareholders
May 13, 2021 11:45 ET
|
Kiadis Pharma Netherlands B.V.
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that...
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
April 29, 2021 01:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 17 paragraph 4 of the...
Delisting of Kiadis will be effective on 25 May 2021
April 26, 2021 12:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the recommended public offer by the Offeror...
Sanofi completes Kiadis acquisition
April 16, 2021 12:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the...
Sanofi declares the Offer for Kiadis unconditional
April 13, 2021 01:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2...
Kiadis employee options committed under the Sanofi Offer
April 09, 2021 01:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the...
Kiadis Pharma announces annual results for the year ended December 31, 2020
April 07, 2021 11:45 ET
|
Kiadis Pharma Netherlands B.V.
New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”,...
Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
March 30, 2021 07:48 ET
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by Sanofi Foreign Participations B.V. (“the Offeror”), a wholly owned subsidiary of Sanofi (“Sanofi”), for...
Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
February 15, 2021 11:45 ET
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit...
Sanofi launches recommended cash offer for all shares in Kiadis
February 12, 2021 01:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article...